Chimeric receives $2.5 M advance on FY25 R&D tax incentive
Filed with ASX · · 2 pages · English
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- CHM CDH17 receives FDA Fast Track
- CHM CDH17 advances to Dose Level 2
- $6.6 million Placement to advance clinical trial pipeline
- ADVENT-AML Phase 1B clinical trial update
- Completion of Entitlement Offer
Later from Chimeric Therapeutics
- CHM CDH17 Clinical Trial Update
- Appendix 4E and Annual Report
- Disease control and tumour shrinkage observed in CHM CDH17
- Additional complete responses in CHM CORE-NK Phase 1b trial
- Response to ASX Query Letter
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics